Payment overview · 2025
General Payments
$1,696.25
90 reported records · 18 companies
Healthcare provider profile · identity verified
Leo Paul Blaize, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BATON ROUGE, LA · NPI 1578563177
Verified facts
What the public records show
CMS Open Payments records show Leo Paul Blaize, M.D. received $1,696.25 in general payments during 2025 across 90 reported records.
GlaxoSmithKline, LLC. accounted for 19.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Mounjaro, Nurtec Odt, Ozempic, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 245 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 245 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $329.12 | 19.4% | 17 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $178.47 | 10.5% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $164.71 | 9.7% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $163.70 | 9.7% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $163.46 | 9.6% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $142.05 | 8.4% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $96.27 | 5.7% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $91.92 | 5.4% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $64.77 | 3.8% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $62.46 | 3.7% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $54.57 | 3.2% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $34.20 | 2.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $31.45 | 1.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.33 | 1.9% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $30.97 | 1.8% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.80 | 1.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.57 | 0.9% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.43 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,696.25 | 90 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $206.93 | 14 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $201.85 | 10 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $148.35 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $140.99 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $133.46 | 7 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $127.27 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $104.10 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $103.33 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $103.33 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $96.27 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $91.92 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $80.23 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $71.34 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $64.77 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $62.46 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $54.57 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $53.47 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $53.23 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $40.60 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $37.48 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $34.20 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $32.52 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $31.97 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $31.45 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $31.33 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $30.97 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $25.80 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $8.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 178 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 88 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 245 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 183 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 131 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 43 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
79 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
88 | 20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
245 | 58 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
245 | 58 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
183 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
131 | 26 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
178 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 924 | 254 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 664 | 194 |
| Atorvastatin Calcium | Atorvastatin Calcium | 560 | 178 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 406 | 115 |
| Levothyroxine Sodium | Levothyroxine Sodium | 355 | 103 |
| Pantoprazole Sodium | Pantoprazole Sodium | 312 | 87 |
| Metformin Hcl Er | Metformin Hcl | 288 | 86 |
| Gabapentin | Gabapentin | 271 | 69 |
| Losartan Potassium | Losartan Potassium | 252 | 72 |
| Jardiance | Empagliflozin | 245 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 232 | 72 |
| Alprazolam | Alprazolam | 212 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 199 | 59 |
| Mounjaro | Tirzepatide | 183 | 32 |
| Eliquis | Apixaban | 178 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 168 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 164 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 161 | 25 |
| Omeprazole | Omeprazole | 158 | 48 |
| Lisinopril | Lisinopril | 148 | 47 |
| Trazodone Hcl | Trazodone Hcl | 147 | 34 |
| Clonazepam | Clonazepam | 131 | 18 |
| Ozempic | Semaglutide | 131 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 126 | 27 |
| Furosemide | Furosemide | 120 | 38 |
| Sertraline Hcl | Sertraline Hcl | 113 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 111 | 28 |
| Ezetimibe | Ezetimibe | 107 | 34 |
| Montelukast Sodium | Montelukast Sodium | 105 | 29 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 105 | 24 |
| Meloxicam | Meloxicam | 101 | 30 |
| Metformin Hcl | Metformin Hcl | 98 | 29 |
| Valsartan | Valsartan | 98 | 28 |
| Belsomra | Suvorexant | 96 | 19 |
| Allopurinol | Allopurinol | 95 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 94 | 28 |
| Vascepa | Icosapent Ethyl | 94 | 22 |
| Tramadol Hcl | Tramadol Hcl | 90 | 20 |
| Farxiga | Dapagliflozin Propanediol | 88 | 20 |
| Finasteride | Finasteride | 88 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 88 | 24 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 88 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 85 | 38 |
| Simvastatin | Simvastatin | 84 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 83 | 16 |
| Potassium Chloride | Potassium Chloride | 80 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 26 |
| Spironolactone | Spironolactone | 79 | 24 |
| Synthroid | Levothyroxine Sodium | 79 | 15 |
| Bupropion Xl | Bupropion Hcl | 78 | 23 |
| Alendronate Sodium | Alendronate Sodium | 71 | 18 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 70 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 67 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 64 | 23 |
| Ondansetron Odt | Ondansetron | 60 | 27 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 60 | 18 |
| Carvedilol | Carvedilol | 58 | 18 |
| Donepezil Hcl | Donepezil Hcl | 58 | 15 |
| Promethazine Hcl | Promethazine Hcl | 57 | 11 |
| Xarelto | Rivaroxaban | 56 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 53 | 16 |
| Topiramate | Topiramate | 52 | suppressed |
| Trulicity | Dulaglutide | 52 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 50 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 46 | suppressed |
| Atenolol | Atenolol | 45 | 14 |
| Mirtazapine | Mirtazapine | 44 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 33 |
| Linzess | Linaclotide | 43 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | 11 |
| Lorazepam | Lorazepam | 42 | suppressed |
| Memantine Hcl | Memantine Hcl | 42 | suppressed |
| Pregabalin | Pregabalin | 42 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 40 | 11 |
| Estradiol | Estradiol | 39 | suppressed |
| Methocarbamol | Methocarbamol | 39 | 14 |
| Glyxambi | Empagliflozin/Linagliptin | 38 | suppressed |
| Temazepam | Temazepam | 38 | suppressed |
| Cefdinir | Cefdinir | 37 | 28 |
| Prednisone | Prednisone | 37 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 36 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | suppressed |
| Eplerenone | Eplerenone | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Glimepiride | Glimepiride | 34 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Famotidine | Famotidine | 33 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 33 | suppressed |
| Myrbetriq | Mirabegron | 33 | 11 |
| Valacyclovir | Valacyclovir Hcl | 33 | 20 |
| Repatha Sureclick | Evolocumab | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 26 | suppressed |
| Eszopiclone | Eszopiclone | 26 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 26 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 25 | suppressed |
| Nadolol | Nadolol | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Lactulose | Lactulose | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 12 |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Alprazolam Er | Alprazolam | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Dextroamphetamine Sulfate Er | Dextroamphetamine Sulfate | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,696.25 · 90 records | GlaxoSmithKline, LLC. | AIRSUPRA, AREXVY, Auvelity, BREZTRI, CONTRAVE, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, GVOKE HYPOPEN, JARDIANCE, KISUNLA, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error